{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-22-000029","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.209324+00:00","generated_at":"2026-06-24T01:03:26.140081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track","bullets":["Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.","Cash and equivalents $245.4M as of June 30, 2022; runway into at least 2026.","TP-03 met all endpoints in Saturn-2 Phase 3; NDA submission expected in H2 2022.","Initiated Ersa Phase 2a trial of TP-03 for Meibomian Gland Disease.","Expecting Phase 1b data for TP-05 Lyme disease prevention in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-22-000029","json":"https://secwatch.observer/filing/0001819790-22-000029.json","markdown":"https://secwatch.observer/filing/0001819790-22-000029.md","text":"https://secwatch.observer/filing/0001819790-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/0001819790-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/tars-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:03:26.140081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}